The Journal of Urology
Volume 184, Issue 2 , Pages 423-431 , August 2010

Cadherin Switching and Bladder Cancer

  • Richard T. Bryan

      Affiliations

    • School of Cancer Sciences, University of Birmingham, Birmingham, United Kingdom
    • Department of Public Health, Epidemiology and Biostatistics, University of Birmingham, Birmingham, United Kingdom
    • Corresponding Author InformationCorrespondence: Bladder Cancer Prognosis Programme, Public Health Building, University of Birmingham, Edgbaston, Birmingham B15 2TT, United Kingdom (telephone: +44-7785-396958)
    • Financial interest and/or other relationship with Olympus (UK).
    • ,
  • Chris Tselepis

      Affiliations

    • School of Cancer Sciences, University of Birmingham, Birmingham, United Kingdom

Received 14 October 2009

References 

  1. van Rhijn BW, Burger M, Lotan Y, et al. Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy. Eur Urol. 2009;Epub ahead of print
  2. Ploeg M, Aben KK, Kiemeney LA. The present and future burden of urinary bladder cancer in the world. World J Urol. 2009;27:289
  3. Horner MJ, Ries LAG, Krapcho M, et al. SEER Cancer Statistics Review, 1975–2006. Bethesda, Maryland: National Cancer Institute; 2009;
  4. Lorusso V, Silvestris N. Systemic chemotherapy for patients with advanced and metastatic bladder cancer: current status and future directions. Ann Oncol. 2005;16(suppl.):iv85
  5. Wallace DM, Bryan RT, Dunn JA, et al. Delay and survival in bladder cancer. BJU Int. 2002;89:868
  6. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data: Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Eur Urol. 2005;48:202
  7. Donat SM, Shabsigh A, Savage C, et al. Potential impact of postoperative early complications on the timing of adjuvant chemotherapy in patients undergoing radical cystectomy: a high-volume tertiary cancer center experience. Eur Urol. 2009;55:177
  8. Shabsigh A, Korets R, Vora KC, et al. Defining early morbidity of radical cystectomy for patients with bladder cancer using a standardized reporting methodology. Eur Urol. 2009;55:164
  9. Cavallaro U, Schaffhauser B, Christofori G. Cadherins and the tumour progression: is it all in a switch?. Cancer Lett. 2002;176:123
  10. Hulpiau P, van Roy F. Molecular evolution of the cadherin superfamily. Int J Biochem Cell Biol. 2009;41:349
  11. Jeanes A, Gottardi CJ, Yap AS. Cadherins and cancer: how does cadherin dysfunction promote tumor progression?. Oncogene. 2008;27:6920
  12. Stemmler MP. Cadherins in development and cancer. Mol Biosyst. 2008;4:835
  13. De Wevel O, Pauwels P, De Craene B, et al. Molecular and pathological signatures of epithelial-mesenchymal transitions at the cancer invasion front. Histochem Cell Biol. 2008;130:481
  14. Wheelock MJ, Shintani Y, Maeda M, et al. Cadherin switching. J Cell Sci. 2008;121:727
  15. Yilmaz M, Christofori G. EMT, the cytoskeleton, and cancer cell invasion. Cancer Metastasis Rev. 2009;28:15
  16. Bryan RT, Atherfold PA, Yeo Y, et al. Cadherin switching dictates the biology of transitional cell carcinoma of the bladder: ex vivo and in vitro studies. J Pathol. 2008;215:184
  17. Hardy RG, Tselepis C, Hoyland J, et al. Aberrant P-cadherin expression is an early event in hyperplastic and dysplastic transformation in the colon. Gut. 2002;50:513
  18. Rieger-Christ KM, Cain JW, Braasch JW, et al. Expression of classic cadherins type I in urothelial neoplastic progression. Hum Pathol. 2001;32:18
  19. Nollet F, Kools P, van Roy F. Phylogenetic analysis of the cadherin superfamily allows identification of six major subfamilies besides several solitary members. J Mol Biol. 2000;299:551
  20. Nose A, Takeichi M. A novel cadherin cell adhesion molecule: its expression patterns associated with implantation and organogenesis of mouse embryos. J Cell Biol. 1986;103:2649
  21. Kemler R, Babinet C, Eisen H, et al. Surface antigen in early differentiation. Proc Natl Acad Sci U S A. 1977;74:4449
  22. Radice GL, Rayburn H, Matsunami H, et al. Developmental defects in mouse embryos lacking N-cadherin. Dev Biol. 1997;181:64
  23. Shimoyama Y, Hirohashi S, Hirano S, et al. Cadherin cell-adhesion molecules in human epithelial tissues and carcinomas. Cancer Res. 1989;49:2128
  24. Radice GL, Ferreira-Cornwell MC, Robinson SD, et al. Precocious mammary gland development in P-cadherin-deficient mice. J Cell Biol. 1997;139:1025
  25. Shimoyama Y, Yoshida T, Terada M, et al. Molecular cloning of a human Ca2+-dependent cell-cell adhesion molecule homologous to mouse placental cadherin: its low expression in human placental tissues. J Cell Biol. 1989;109:1787
  26. Hatta K, Okada TS, Takeichi M. A monoclonal antibody disrupting calcium-dependent cell-cell adhesion of brain tissues: possible role of its target antigen in animal pattern formation. Proc Natl Acad Sci U S A. 1985;82:2789
  27. Takeichi M. The cadherins: cell-cell adhesion molecules controlling animal morphogenesis. Development. 1988;102:639
  28. Friedl P, Gilmour D. Collective cell migration in morphogenesis, regeneration and cancer. Nat Rev Mol Cell Biol. 2009;10:445
  29. Chiang AC, Massague J. Molecular basis of metastasis. N Engl J Med. 2008;359:2814
  30. Tselepis C, Perry I, Jankowski J. Barrett's esophagus: disregulation of cell cycling and intercellular adhesion in the metaplasia-dysplasia-carcinoma sequence. Digestion. 2000;61:1
  31. Maeda M, Johnson KR, Wheelock MJ. Cadherin switching: essential for behavioral but not morphological changes during an epithelium-to-mesenchyme transition. J Cell Sci. 2005;118:873
  32. Mandeville JA, Silva Neto B, Vanni AJ, et al. P-cadherin as a prognostic indicator and a modulator of migratory behaviour in bladder carcinoma cells. BJU Int. 2008;102:1707
  33. Ribeiro AS, Albergaria A, Sousa B, et al. Extracellular cleavage and shedding of P-cadherin: a mechanism underlying the invasive behaviour of breast cancer cells. Oncogene. 2009;
  34. Nieman MT, Prudoff RS, Johnson KR, et al. N-cadherin promotes motility in human breast cancer cells regardless of their E-cadherin expression. J Cell Biol. 1999;147:631
  35. Taniuchi K, Nakagawa H, Hosokawa M, et al. Overexpressed P-cadherin/CDH3 promotes motility of pancreatic cancer cells by interacting with p120ctn and activating rho-family GTPases. Cancer Res. 2005;65:3092
  36. Gravdal K, Halvorsen OJ, Haukaas SA, et al. A switch from E-cadherin to N-cadherin expression indicates epithelial to mesenchymal transition and is of strong and independent importance for the progress of prostate cancer. Clin Cancer Res. 2007;13:7003
  37. Jaggi M, Nazemi T, Abrahams NA, et al. N-cadherin switching occurs in high Gleason grade prostate cancer. Prostate. 2006;66:193
  38. Patel IS, Madan P, Getsios S, et al. Cadherin switching in ovarian cancer progression. Int J Cancer. 2003;106:172
  39. Li G, Satyamoorthy K, Herlyn M. N-cadherin-mediated intercellular interactions promote survival and migration of melanoma cells. Cancer Res. 2001;61:3819
  40. Tani T, Laitinen L, Kangas L, et al. Expression of E- and N-cadherin in renal cell carcinomas, in renal cell carcinoma cell lines in vitro and in their xenografts. Int J Cancer. 1995;64:407
  41. Esteban MA, Tran MG, Harten SK, et al. Regulation of E-cadherin expression by VHL and hypoxia-inducible factor. Cancer Res. 2006;66:3567
  42. Faraldo MM, Teuliere J, Deugnier MA, et al. Beta-catenin regulates P-cadherin expression in mammary basal epithelial cells. FEBS Lett. 2007;581:831
  43. Bauer K, Dowejko A, Bosserhoff AK, et al. P-cadherin induces an epithelial-like phenotype in oral squamous cell carcinoma by GSK-3beta-mediated snail phosphorylation. Carcinogenesis. 2009;30:1781
  44. Jarrard DF, Paul R, van Bokhoven A, et al. P-cadherin is a basal cell-specific epithelial marker that is not expressed in prostate cancer. Clin Cancer Res. 1997;3:2121
  45. Milicic A, Harrison LA, Goodlad RA, et al. Ectopic expression of P-cadherin correlates with promoter hypomethylation early in colorectal carcinogenesis and enhanced intestinal crypt fission in vivo. Cancer Res. 2008;68:7760
  46. Bringuier PP, Umbas R, Schaafsma HE, et al. Decreased E-cadherin immunoreactivity correlates with poor survival in patients with bladder tumors. Cancer Res. 1993;53:3241
  47. Lascombe I, Clairotte A, Fauconnet S, et al. N-cadherin as a novel prognostic marker of progression in superficial urothelial tumors. Clin Cancer Res. 2006;12:2780
  48. Baumgart E, Cohen MS, Silva Neto B, et al. Identification and prognostic significance of an epithelial-mesenchymal transition expression profile in human bladder tumors. Clin Cancer Res. 2007;13:1685
  49. Rieger-Christ KM, Lee P, Zagha R, et al. Novel expression of N-cadherin elicits in vitro bladder cell invasion via the Akt signaling pathway. Oncogene. 2004;23:4745
  50. Wallerand H, Cai Y, Wainberg ZA, et al. Phospho-Akt pathway activation and inhibition depends on N-cadherin or phospho-EGFR expression in invasive human bladder cancer cell lines. Urol Oncol. 2010;28:180

PII: S0022-5347(10)03318-5

doi: 10.1016/j.juro.2010.04.016

The Journal of Urology
Volume 184, Issue 2 , Pages 423-431 , August 2010

Article Tools

* Image Usage & Resolution